COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

TU 025 Keishi Bukuryo Gan for Post-menopausal Hot Flash Management

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00119418
Recruitment Status : Completed
First Posted : July 13, 2005
Last Update Posted : October 26, 2010
Tsumura and Company, Tokyo, Japan
University of Minnesota
Information provided by:
Plotnikoff, Gregory A., M.D.

Brief Summary:
This study tests to see if TU 025 Keishi Bukuryo Gan reduces the frequency and severity of hot flashes in post-menopausal American women. This study will also estimate the best dose amount and determine the common short-term side effects and risks.

Condition or disease Intervention/treatment Phase
Hot Flashes Menopause Drug: TU 025 Keishi Bukuryo Gan Phase 2

Detailed Description:

Menopause is a natural transition in a woman's hormonal state associated with the cessation of ovulation and menstruation. For approximately 80% of peri-menopausal women, menopause may be defined by the experience of uncomfortable symptoms such as hot flashes, night sweats, dyspareunia, urinary frequency, sleep disturbance, fatigue, depression and anxiety.

Hot flashes are the most common complaint of perimenopausal and postmenopausal Western women. Approximately 10-20% of postmenopausal women find such symptoms nearly intolerable. Nearly one-third of postmenopausal women experience disruptive hot flashes for 5 years after natural menopause and approximately 20% experience hot flashes for 15 years.

Menopause has been understood as an estrogen deficiency state from which women are placed at great risk for osteoporosis, colon cancer and heart disease. For symptom management, as well as for disease prevention, the medical response for 20 years has been hormone replacement therapy (HRT). In recent years, as many as 38% of US women between ages 50 and 74 years were using HRT.

For menopause hormone therapy, in 2005, counseling patients from an evidence-based perspective means informing patients of the significantly increased risk of dementia, breast cancer,endometrial cancer,venous thromboembolism and gallbladder disease. Additionally, physicians must also state that hormone therapy increases the risk of cardiovascular events (heart attack or strokes) in women with or without pre-existing heart disease. Furthermore, well-done studies demonstrate that hormone therapy does not enhance health-related quality of life.

For this reason, there is great interest in non-hormonal alternatives for menopausal hot flash management. The current standard of care, based on controlled clinical trials in women with breast cancer, is the use of SSRI anti-depressants such as venlafaxine. However, many women seek other options.

In Japan, TJ25 Keishi Bukuryo Gan is a leading non-hormonal prescription agent for management of menopausal hot flashes. However, no clinical data exists on its effectiveness in American women.

This is a pilot phase II clinical study to estimate the effectiveness of TU-25 Keishi Bukuryo Gan for reduction of both the severity and the frequency of hot flashes in healthy postmenopausal American women. This study will also estimate the best dose and determine the common short-term side effects and risks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: TU 025 Keishi Bukuryo Gan for Post-Menopausal Hot Flash Management
Study Start Date : November 2004
Study Completion Date : February 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Menopause

Primary Outcome Measures :
  1. frequency and severity of hot flashes by Mayo Hot Flash Diary

Secondary Outcome Measures :
  1. sleep quality by the Pittsburgh Questionnaire
  2. bodyweight/BMI by standard measurements
  3. quality of menopausal life by Greene Climacteric Scale
  4. lipid profile by laboratory test
  5. liver function profile by laboratory test
  6. hormone profile by laboratory test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 58 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Post-menopausal women aged 45-58 with an adequate hot flash frequency severity score. Post-menopause is defined as amenorrhea for at least 12 months, or post-hysterectomy for more than one year with follicle-stimulating hormone levels greater than or equal to 40 mIU/mL and estradiol (E2) levels of less than or equal to 20 pg/mL, or greater than two months post oophorectomy.
  • All subjects must be up to date with both pap and mammogram screening by the US Preventative Services Taskforce Guidelines for the length of the trial.
  • All subjects on any prescription medication need the approval of their prescribing physician for participation in the trial.

Exclusion Criteria:

  • Concurrent hot flash therapies (prescription medications including hormones, antidepressants, SERMs, gabapentin or over the counter supplements)
  • Moderately severe disease state(s) or diseases that affect absorption/metabolism, or diseases that mimic menopausal hot flashes.
  • Inability to swallow vitamin size pills
  • Beck depression inventory score greater than 11
  • Greater than 10 cigarettes per day
  • Abnormal liver function
  • Treated or untreated hypertension greater than 160/90.
  • BMI greater than 36
  • Inability to give consent or commit to the length of the trial
  • Known hypersensitivity to ingredients
  • Physician judgment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00119418

Layout table for location information
United States, Minnesota
University of Minnesota General Clinical Research Center
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Plotnikoff, Gregory A., M.D.
Tsumura and Company, Tokyo, Japan
University of Minnesota
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00119418    
Other Study ID Numbers: 0402M56292
M01-RR00400 NIH
First Posted: July 13, 2005    Key Record Dates
Last Update Posted: October 26, 2010
Last Verified: July 2005
Keywords provided by Plotnikoff, Gregory A., M.D.:
hot flash
herbal medicine
alternative medicine
Additional relevant MeSH terms:
Layout table for MeSH terms
Hot Flashes